RedHill Biopharma says it’s getting good results in clinical trials using ondansetron pills to help alleviate side effects such as nausea, vomiting and diarrhea among people using the blockbuster ...
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced development progress for RHB-102 (Bekinda®) in multiple GI indications, ...
TEL-AVIV/RALEIGH - RedHill Biopharma Ltd. (NASDAQ:RDHL) is advancing development of RHB-102, a once-daily oral ondansetron formulation, to address gastrointestinal side effects associated with ...
InvestorsHub on MSN
RedHill Biopharma shares jump on progress toward treating GLP-1 side effects
RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances in the development of RHB-102 (Bekinda), a therapy aimed at addressing ...
According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...
Cancer patients can ward off waves of vomiting after treatment with a relatively cheap anti-nausea pill, but some are running into coverage limits. Doctors say restrictions on the number of tablets ...
Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback